What is the recommended daily maintenance dose of phenytoin for adults, and how should it be adjusted for children, hepatic impairment, congestive heart failure, or interacting medications?

Daily Phenytoin Dosing

For adults, the standard daily maintenance dose of phenytoin is 300 mg/day (typically given as 100 mg three times daily), with a usual therapeutic range of 4-8 mg/kg/day, though doses may need adjustment based on serum levels and clinical response. 1

Adult Dosing

Standard Maintenance Dosing

• Initial dose: 100 mg three times daily (300 mg/day total) 1
• Typical maintenance range: 300-400 mg/day 1
• Maximum recommended: 600 mg/day per FDA labeling, though clinical practice occasionally exceeds this 1
• Therapeutic serum level target: 10-20 mcg/mL 1

Important Timing Considerations

• Allow 7-10 days to reach steady-state before making dose adjustments 1
• Once seizure control is established with 300 mg/day in divided doses, once-daily dosing may be considered using extended-release formulations only 1

Dose Adjustments

• Increase in weekly increments of 50-100 mg if seizure control inadequate 1
• Due to Michaelis-Menten (nonlinear) kinetics, small dose changes (25-50 mg) are critical when serum levels reach 5-10 mcg/mL, as the concentration-to-dose relationship becomes steep 2

Pediatric Dosing

Children require weight-based dosing:

• Initial: 5 mg/kg/day divided into 2-3 doses 1
• Maintenance: 4-8 mg/kg/day (maximum 300 mg/day) 1
• Children >6 years and adolescents: May require minimum adult dose of 300 mg/day 1

For status epilepticus in children: 20 mg/kg IV loading dose (maximum 1000 mg), infused at ≤1 mg/kg/min 3

Special Populations Requiring Dose Reduction

Age-Related Adjustments

Elderly patients (60-79 years) require approximately 21% less phenytoin than younger adults (20-39 years) to maintain the same serum concentration due to declining metabolic capacity (Vmax) with age 4. For a target level of 15 mcg/mL:

• Ages 20-39: Average Vmax 7.5 mg/kg/day
• Ages 60-79: Average Vmax 6.0 mg/kg/day

Hepatic Impairment

• Reduce initial doses and monitor closely
• Hepatic dysfunction decreases phenytoin metabolism, increasing risk of toxicity
• More frequent serum level monitoring essential

Congestive Heart Failure

• Use with caution - phenytoin may cause negative inotropic effects, prolonged QT interval, and cardiac dysrhythmias 3
• Consider lower initial doses with careful cardiac monitoring

Renal Impairment

• Dose reduction necessary - reduced kidney function increases phenytoin clearance requirements 5
• Patients with elevated serum creatinine require lower maintenance doses
• The protein-unbound fraction may increase, requiring monitoring of free phenytoin levels

Drug Interactions Requiring Dose Adjustment

Medications That Decrease Phenytoin Levels (Require Dose Increase)

• Carbamazepine: Tends to decrease phenytoin levels 6
• Phenobarbital: May increase phenytoin clearance, requiring higher fosphenytoin doses 5

Medications That Increase Phenytoin Levels (Require Dose Decrease)

• Acetazolamide: Tends to increase phenytoin levels 6

Critical Monitoring Points

Serum Level Monitoring

• Target therapeutic range: 10-20 mcg/mL (total phenytoin) 1
• Check levels after 7-10 days at steady state 1
• With oral loading, therapeutic levels achieved in 3-8 hours 7
• With IV loading (18-20 mg/kg), therapeutic levels achieved within minutes of infusion completion 7

Common Pitfalls to Avoid

1. Making dose changes too quickly: Wait 7-10 days between adjustments 1

2. Using large dose increments at higher serum levels: When levels reach 5-10 mcg/mL, switch to 25-50 mg increments due to nonlinear kinetics 2

3. Switching formulations without monitoring: Extended-release vs. immediate-release products have different absorption characteristics - monitor serum levels closely when changing brands or formulations 1

4. Ignoring the 8% difference between salt forms: Free acid phenytoin (in suspension/chewable tablets) contains ~8% more drug than phenytoin sodium (in capsules) - dose adjustments may be needed when switching 1

5. Overlooking age-related metabolism changes: Elderly patients require lower doses 4

6. Failing to account for protein binding changes: In hypoalbuminemia or renal failure, measure free phenytoin levels rather than total levels

7. Not recognizing time-dependent clearance with fosphenytoin: Prolonged fosphenytoin use (>3 days) may cause time-dependent increases in phenytoin clearance, requiring maintenance dose increases to prevent breakthrough seizures 8